US Bancorp’s Tango Therapeutics TNGX Stock Holding History

US Bancorp’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.56K	Buy	146 +98	+204%	+$2.42K	﹤0.01%	3683
2026 Q1	$1K	Buy	+48	New	+$668	﹤0.01%	3932
2025 Q4	–	Sell	-53	Closed	-$445	–	4199
2025 Q3	$445	Sell	53 -6,136	-99%	-$41.5K	﹤0.01%	3878
2025 Q2	$31.7K	Sell	6,189 -611	-9%	-$1.51K	﹤0.01%	2990
2025 Q1	$9.32K	Sell	6,800 -197	-3%	-$484	﹤0.01%	3459
2024 Q4	$21.6K	Buy	6,997 +6,732	+2,540%	+$31.3K	﹤0.01%	3124
2024 Q3	$2.04K	Sell	265 -302	-53%	-$2.88K	﹤0.01%	3780
2024 Q2	$4.87K	Buy	567 +103	+22%	+$796	﹤0.01%	3524
2024 Q1	$3.68K	Hold	464	–	–	﹤0.01%	3597
2023 Q4	$4.59K	Buy	+464	New	+$4.03K	﹤0.01%	3553

Other funds holding TNGX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

US Bancorp's TNGX Position: Q2 2026 in Review

US Bancorp increased its Tango Therapeutics (TNGX) stake by 204% in Q2 2026, buying an estimated $2.42K and bringing the position to 146 shares worth $4.56K. The position accounts for ﹤0.01% of the portfolio, ranked #3683.

US Bancorp first reported a position in TNGX in Q4 2023 and has held it in 10 quarters since. The position peaked at $31.7K in Q2 2025. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

US Bancorp held 146 shares of Tango Therapeutics worth $4.56K as of Q2 2026.
US Bancorp bought 98 Tango Therapeutics shares in Q2 2026, an estimated $2.42K.
Tango Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3683 holding.
US Bancorp first reported a position in Tango Therapeutics in Q4 2023 and has held it in 10 quarters since.
US Bancorp's Tango Therapeutics position peaked at $31.7K in Q2 2025.
248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.